Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial
Primary result · Percentage change in body weight from baselineResult — go to the resultBetween-group difference −15.15 % 95% CI −17.22% to −13.09%Authors' conclusion
Mazdutide provided clinically meaningful weight reduction in Chinese adults with moderate to severe obesity compared with placebo, but participants receiving the drug experienced gastrointestinal adverse reactions compared with those receiving placebo.
Study context
- Population
- Chinese adults with obesity (BMI ≥30), with or without T2D; 27 hospitals, December 2023 to November 2025461 received treatment, analysed
- Participants
- 308 vs 154
- Comparison
- Once-weekly SC mazdutide 9 mg vs placebo, adjunct to reduced-calorie diet and increased physical activity, 60 weeks
- Mazdutiden = 308
- Placebon = 154reference
- Primary endpoint
- Coprimary: percentage change in body weight from baseline and weight reduction of ≥5%
- Follow-up
- Week 60
Methodological detailsdouble-blind, placebo-controlled, phase 3, multicentre (27 hospitals), randomized 2:1
- Double-blind
- Placebo-controlled
- Phase 3
- Multicentre (27 hospitals)
- Randomized 2:1
Primary result
Percentage change in body weight from baseline
Between-group difference
−15.15 %
95% CI −17.22% to −13.09%
P < 0.001
Change by group
Mazdutide
−16.65
mean · 95% CI −18.19%–-15.12% · %
Placebo
−1.50
mean · 95% CI −3.43%–0.43% · %
Mazdutidevs Placebo
between-group difference −15.15 % (95% CI −17.22% to −13.09%); P < 0.001
As reported in the abstract
Further findings
| Outcome | Mazdutide | Placebo | Between-group difference (95% CI) | P value | |
|---|---|---|---|---|---|
| Coprimary: body weight reduction ≥5% · week 60Coprimary outcome | 84.3% | 33.1% | 51.6% (43.0%–60.1%) | P < 0.001 | |
| −50050100Difference (linear scale) |
Safety
AEs leading to treatment discontinuation
Most common AEs
Vomiting
Nausea
Diarrhea
Most common AEs
- Most AEs were mild to moderate in severity
Original publication
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. Published 4 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →